₽EPA

Case Study: Application of Dose-Response Model Averaging to Chloroform

By Todd Blessinger Workshop: Advancing Quantitative Analysis in Human Health Assessments through Probabilistic Methods 10/08/24

Office of Research and Development Center for Public Health and Environmental Assessment



• Disclaimer: The views expressed in this presentation are those of the author and do not necessarily represent the views or the policies of the U.S. Environmental Protection Agency.



- Case study summary
- Prior distributions
- Examples of model averaging applied to selected chloroform endpoints
- Sensitivity analysis




- To ground the evaluation of model averaging in current efforts, this case study uses datasets being considered in an in-development draft IRIS¹ toxicological review of chloroform-inhalation.
- Bayesian model averaging was applied to a collection of dichotomous endpoints from chloroform animal studies.
- Constructing model weights was done using a Laplace approximation, as included in BMDS² (Wheeler et al., 2020).
- Analysis done in the R package ToxicR.
- Both the BMDS priors (v 3.3) and ToxicR priors were applied.
- Sensitivity analysis conducted by varying the priors with higher and lower variance.

Models and Prior Distributions

• Models included for model averaging:

SFPA

• Quantal-linear, multistage (degree 2), Weibull, gamma, dichotomous Hill, logistic, log-logistic, probit, log-probit



Models and Prior distributions

- All parameter prior distributions had the form normal or lognormal.
- Example: Priors for log-logistic model in BMDS and ToxicR

$$p(x) = g + \frac{1-g}{1 + \exp[-\alpha - \beta \log x]}$$

| Distribution | Parameter | Mean ^a | SD ^a |
|--------------|-----------|-------------------|-----------------|
| Normal | g^{b} | 0 | 2 |
| Normal | α | 0 | 1 |
| Lognormal | β | 0.69315 | 0.5 |

^aFor the lognormal prior, values are the log-mean and log-SD. ${}^{b}logit(g)$ has normal prior.

FPA

©EPA Prior distributions

• Example: Priors for Weibull model in BMDS and ToxicR

$$p(x) = g + (1-g)[1 - \exp(-\beta x^{\alpha})]$$

| Distribution | Parameter | BMDS Mean ^a | BMDS SD ^a | ToxicR Mean ^a | ToxicR SD ^a |
|--------------|-----------------|---------------------------|-------------------------|-----------------------------|---------------------------|
| Normal | $g^{	extsf{b}}$ | 0 | 2 | 0 | 2 |
| Lognormal | β | 0.69315 | 0.42426 | 0.42426 | 0.5 |
| Lognormal | α | 0 | 1 | 0 | 1.5 |


^aFor the lognormal priors, values are the log-mean and log-SD. ^blogit(g) has normal prior.

• BMDS and ToxicR mostly yielded similar results.



• Dose-response data:

| Internal dose (mg/L-d) | 0 | 28.7 | 45.0 | 60.2 |
|------------------------|--------|--------|--------|---------|
| Response | 0 / 50 | 0 / 50 | 5 / 50 | 38 / 49 |



Dose



Model average results from ToxicR (BMDS priors)

| Model | BMD (BMDL, BMDU) | Pr(M Data) |
|----------------|------------------------------|------------|
| Probit | 41.95 (38.00 ,45.01) | 0.488 |
| Log-Probit | 44.00 (40.40 ,46.91) | 0.428 |
| Weibull | 46.02) <i>,</i> 46.03 (37.93 | 0.037 |
| Log-Logistic | 43.15 (39.16 ,46.41) | 0.033 |
| Hill | 43.16 (39.27 <i>,</i> 46.30) | 0.013 |
| Logistic | ,42.10 <i>,</i> 38.48 (33.97 | 0.001 |
| Quantal-Linear | 13.22 (10.32 ,17.37) | 0.000 |
| Multistage | (21.69, 17.70 (13.66) | 0.000 |
| Gamma | ,37.92 <i>,</i> 33.11 (27.15 | 0.000 |

Model Average BMD: 42.90 (38.60, 46.23) 90.0% CI



• BMD results:

| Method | BMD (mg/L-d) | BMDL (mg/L-d) |
|-----------------------------|--------------|---------------|
| Maximum likelihood (probit) | 45.0 | 41.8 |
| Model average (BMDS priors) | 42.9 | 38.6ª |

^aModel average BMDL is 8% lower than maximum likelihood BMDL.




8.0

0.0

10

Model : Dichotomous MA, Fit type : Laplace



0.6 0.0 0.4 0.2

Model average (Bayesian)

30

Dose

40

50

60

20

Single model (maximum likelihood)



Example: Hepatic lesions in female mice (Larson, 1996)

• Dose-response data:

| Internal dose (mg/L-d) | 0 | 7 | 46.8 | 237 | 729 | 2240 |
|------------------------|--------|------|--------|--------|---------|---------|
| Response | 1 / 15 | 1/15 | 5 / 14 | 4 / 14 | 10 / 15 | 15 / 15 |


• BMD results:

| Method | BMD (mg/L-d) | BMDL (mg/L-d) |
|--|--------------|-------------------|
| Maximum likelihood (quantal-linear) | 66.8 | 43.8 |
| Model average (BMDS priors) | 112.5 | 52.0 ^a |


^aModel average BMDL is 19% higher than maximum likelihood BMDL.



Example: Hepatic lesions in female mice (Larson, 1996)



Single model (maximum likelihood)



Model average (Bayesian)



Example: Kidney lesions in male mice (Larson, 1996)

• Dose-response data:


| Internal dose (mg/L-d) | 0 | 6.3 | 41.4 | 190 | 451 | 736 |
|------------------------|------|--------|------|--------|-------|---------|
| Response | 0/15 | 0 / 15 | 0/14 | 0 / 15 | 11/12 | 14 / 14 |

• BMD results:

| POD | Value (mg/L-d) | Value (mg/L-d) |
|-----------------------------|----------------|-------------------------|
| Traditional | LOAEL = 451 | NOAEL = 190 |
| Model average (BMDS priors) | BMD = 206 | BMDL = 139 ^a |

^aModel average BMDL is 27% lower than NOAEL.

Example: Kidney lesions in male mice (Larson, 1996)



€EPA

Model average (Bayesian)



Example: Respiratory metaplasia in female rats (Yamamoto, 2002)

• Dose-response data:

| Internal dose (mg/L-d) | 0 | 1.79 | 5.36 | 16.1 |
|------------------------|--------|---------|---------|---------|
| Response | 0 / 50 | 43 / 50 | 48 / 50 | 45 / 49 |




Example: Respiratory metaplasia in female rats (Yamamoto, 2002)

| Model average results from ToxicR (BMDS priors) | | | | | |
|---|---------------------------|------------|--|--|--|
| Model | BMD (BMDL, BMDU) | Pr(M Data) | | | |
| | | | | | |
| Hill | 0.04 (0.00 ,0.26) | 0.975 | | | |
| Log-Logistic | 0.00 (0.00 ,0.04) | 0.017 | | | |
| Log-Probit | 0.01 (0.00 ,0.07) | 0.007 | | | |
| Quantal-Linear | 0.25 (0.20 ,0.31) | 0.000 | | | |
| Multistage | 0.28 (0.23 ,0.35) | 0.000 | | | |
| Weibull | 0.00 (0.00 ,0.01) | 0.000 | | | |
| Gamma | 0.00 (0.00 ,0.02) | 0.000 | | | |
| Logistic | 0.70 (0.55 <i>,</i> 0.93) | 0.000 | | | |
| Probit | 0.98 (0.79 <i>,</i> 1.24) | 0.000 | | | |

Model Average BMD: 0.04 (0.00, 0.26) 90.0% CI

Sepa

Example: Respiratory metaplasia in female rats (Yamamoto, 2002)




Model average (Bayesian)




Sensitivity Analysis

- Standard deviation (SD) of every parameter prior for every model multiplied by 2, 5, 10, and 0.5.
- For lognormal priors, additional variation incorporated three ways:
 - Through geometric variance (GV)
 - Through median
 - Half through GV, half through median





| Model average priors (BMDS) | BMD (mg/L-d) | BMDL (mg/L-d) |
|---|--------------|---------------|
| Default | 42.9 | 38.6 |
| 10 SD (for lognormal, all additional variation incorporated through GV) | 44.6 (+4%) | 40.9 (+6%) |
| 10 SD (for lognormal, half additional variation incorporated through GV, half through median) | 44.7 (+4%) | 41.1 (+6%) |
| 10 SD (for lognormal, all additional variation incorporated through median) | 44.9 (+5%) | 41.2 (+7%) |



SFP




Example: Kidney lesions in male mice (Larson, 1996)


| Model average priors | BMD (mg/L-d) | BMDL (mg/L-d) |
|---|--------------|---------------|
| Default | 206 | 139 |
| 10 SD (for lognormal, all additional variation incorporated through GV) | 250 (+21%) | 168 (+21%) |
| 10 SD (for lognormal, half additional variation incorporated through GV, half through median) | 253 (+22%) | 171 (+23%) |
| 10 SD (for lognormal, all additional variation incorporated through median) | 290 (+41%) | 192 (+38%) |

Set EPA


Example: Kidney lesions in male mice (Larson, 1996)



10 SD; half additional variation in GV, half in median



10 SD; all additional variation in GV



10 SD; all additional variation in median



- In many cases (esp. for "well-behaved" datasets), Bayesian model averaging yields results that are not very different from single model selection using maximum likelihood.
- Bayesian model averaging sometimes yields reasonable results for datasets that are not otherwise amenable to modeling.
- For some datasets, modeling is not advised, even with model averaging.
 - Explore assessment of model fit and adequacy of data for modeling.

Set EPA

Acknowledgements and References

- Collaborators: Christine Cai, Colin Peterson, Hyunsu Ju
- Chloroform co-assessment managers: Margaret Pratt, Andre Weaver
- Wheeler, M.W., et al., 2020. Quantitative risk assessment: developing a Bayesian approach to dichotomous dose–response uncertainty. Risk Anal. 40, 1706–1722.
- BMDS: <u>https://www.epa.gov/bmds</u>
- ToxicR: <u>https://github.com/NIEHS/ToxicR</u>